MOR.SG - MORPHOSYS AG Inhaber-Aktien o.N
| Previous close | 115.30 |
| Open | 115.10 |
| Bid | 116.30 x 27700 |
| Ask | 116.80 x 21000 |
| Day's range | 114.60 - 116.70 |
| 52-week range | 80.20 - 116.70 |
| Volume | 3,977 |
| Avg. volume | 1,337 |
| Market cap | N/A |
| Beta (3Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- EQS Group
MorphoSys AG: Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act]
MorphoSys AG / Preliminary announcement on the disclosure of financialstatements17.12.2018 / 14:02Preliminary announcement of the publication of financial reports accordingto Articles 114, 115, 117 of the WpHG [the German Securities Act]transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement. ...
- EQS Group
MorphoSys AG: Preliminary announcement of the publication of quarterly reports and quarterly/interim statements
MorphoSys AG / Preliminary announcement on the disclosure of financialstatements17.12.2018 / 14:02Preliminary announcement of the publication of quarterly reports andquarterly/interim statements transmitted by DGAP - a service of EQS GroupAG.The issuer is solely responsible for the content of this announcement. ...
- EQS Group
MorphoSys AG: Corporate Calendar 2019 (news with additional features)
DGAP-News: MorphoSys AG / Key word(s): Miscellaneous17.12.2018 / 14:00 The issuer is solely responsible for the content of this announcement.
- EQS Group
MorphoSys's Licensee Janssen Announces Data from the Phase 3 Head-to-Head Study ECLIPSE Demonstrating Superiority of Tremfya(R) vs. Cosentyx(R) as Measured by PASI 90 at Week 48 in the Treatment of Plaque Psoriasis (news with additional features)
DGAP-News: MorphoSys AG / Key word(s): Study results12.12.2018 / 13:36 The issuer is solely responsible for the content of this announcement.
- EQS Group
Ad hoc: MorphoSys Announces that According to a Presentation Title at an Upcoming Conference, Guselkumab Demonstrates Superior Long-Term Responses to Secukinumab at Week 48 in the Treatment of Moderate to Severe Psoriasis
MorphoSys AG / Key word(s): MiscellaneousAd hoc: MorphoSys Announces that According to a Presentation Title at an Upcoming Conference, Guselkumab Demonstrates Superior Long-Term Responses to Secukinumab at Week 48 in the Treatment of Moderate to Severe Psoriasis07-Dec-2018 / 13:21 CET/CESTDisclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.